AzTrials
AzTrials

System Lupus Erythematosus(SLE)NCT07470151

Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases

A study testing EVM18001 Injection in people with System Lupus Erythematosus(SLE) and Scleroderma, run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology at 1 site in China.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

A FIH, single arm, open-label, Investigator Initiated Trial (IIT) study to evaluate the safety and tolerability of EVM18001 in the treatment of active refractory autoimmune diseases (SLE, MG, and SSc), and determine the recommended dose for subsequent treatment. Read more about this study

Who is it for?
Ages 18 to 70 years
What is being tested?
EVM18001 Injection
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
12 participants
Where
1 siteChina
Study dates
12 Mar 2026to Dec 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Voluntarily sign the Informed Consent Form (ICF), which must be signed by the participant or their legal guardian.
  • At the time of signing the ICF, the age must be between 18 and 70 years (inclusive), regardless of gender.
  • At screening, peripheral blood B cells must be CD19 positive, and T cells must express CD7.
  • Confirmed autoimmune diseases based on recognized diagnostic criteria, including:
  • SLE: Diagnosed with SLE according to the 2012 Systemic Lupus International Collaborating Clinics (SLICC) or 2019 European League Against Rheumatism (EULAR)/ACR criteria;
  • MG: Diagnosed with MG according to the Myasthenia Gravis Foundation of America (MGFA) clinical classification;
Show all 29Show fewer
  • SSc: Diagnosed with SSc according to the 2013 ACR/EULAR classification criteria.
  • History of autoimmune disease for at least 6 months before screening and meets any of the following criteria. Definitions of active refractory SLE, active refractory SSc, and active refractory MG are as follows:
  • Definition of active refractory SLE: SLEDAI-2000 score ≥6; and disease activity or relapse persists after at least 3 months of standard therapy (glucocorticoids combined with at least 2 immunosuppressants, or at least 1 imunosuppressant and 1 targeted therapy).
  • Definition of active refractory SSc: Patients meeting the 2013 ACR/EULAR classification criteria for SSc who still show disease activity or progression after at least 6 months of standard therapy (including steroids, immunosuppressants, vasodilators, or antifibrotic agents). Specific criteria include but are not limited to: mRSS increase ≥5 points or ≥25% from baseline; absolute value of predicted FVC% decrease ≥5%; DLCO% corrected for hemoglobin absolute value decrease ≥10%; new or worsening digital ulcers after ≥3 months of vasodilator therapy; persistent or recurrent organ involvement requiring intensified treatment.
  • Definition of active refractory MG: Refers to generalized MG patients meeting MGFA diagnostic criteria with ongoing disease activity (MGFA II-IV, QMG ≥12, or MG-ADL ≥6), and includes at least one of the following: poor control after at least 12 months of standard therapy (including at least 2 immunosuppressants); need for ≥2 intravenous immunoglobulin (IVIG) or plasma exchange treatments in the past 12 months to control symptoms; relapse with prednisone ≥20 mg/day or reduction to <10 mg/day; persistent or recurrent disease activity.
  • Patients must meet the following conditions for concomitant medication:
  • Corticosteroids must have been used for more than 6 weeks prior to screening and at a stable dose of ≤ 10 mg/day prednisone or equivalent for at least 14 days prior to administration of EVM18001. Concurrent treatment with topical or inhaled corticosteroids (or other immunomodulators) is allowed;
  • Continued use during treatment is allowed if antimalarial drugs (eg, hydroxychloroquine, chloroquine, etc.) are started ≥ 12 weeks prior to screening and maintained at a stable dose for ≥ 8 weeks (maximum dose limit: hydroxychloroquine, 400 mg/day; chloroquine, 500 mg/day).
  • Examination at screening meet any of the following criteria:
  • SLE: positive for blood ANA, and/or positive for anti-dsDNA, anti-Smith antibodies;
  • MG: Positive serology for anti-AChR antibodies or anti-musclespecific tyrosine kinase receptor (MuSK) antibodies.
  • Life expectancy greater than 6 months.
  • Bone marrow reserve and organ function are normal:
  • Bone marrow function: defined as absolute neutrophil count (ANC) ≥ 1.0×109/L, absolute lymphocyte count (ALC) ≥0.5×109/L, hemoglobin (Hb) ≥80g/L, platelet count (PLT) ≥50×109/L. Blood transfusions and growth factors must not be used to meet these requirements within 7 days prior to screening for eligibility.
  • Coagulation function: defined as international normalized ratio (INR) or activated partial thromboplastin time (aPTT) ≤ 1.5× upper limit of normal (ULN).
  • Cardiac function: defined as left ventricular ejection fraction (LVEF) ≥ 45% as assessed by echocardiography (ECHO).
  • Pulmonary function: defined as Common Terminology Criteria ≤for Adverse Events (CTCAE) Grade 1 dyspnea and oxygen saturation (SpO2) ≥ 92% (pulse oximetry) on room air.
  • Hepatic function: defined as alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5× ULN, total bilirubin < 2.0mg/dL (total bilirubin of Gilbert syndrome trial participants <3.0mg/dL).
  • Renal function: defined as calculated creatinine clearance (Cockcroft-Gault) ≥ 50 mL/min without hydration assistance.
  • Female trial participants of childbearing potential:
  • Negative serum β human chorionic gonadotropin (β-hCG) test at screening;
  • Agree to use a highly effective method of contraception for the duration of study participation and for 12 months after EVM18001 last infusion.
  • Male trial participant whose partner is of childbearing potential who agrees to use a highly effective method of contraception during the study and 12 months after the last infusion of the EVM18001.

Who cannot join

  • Concurrent autoimmune diseases requiring systemic treatment.
  • The autoimmune disease meets the following criteria:
  • SLE: patients with renal crisis;
  • MG: MGFA clinical classification type V or experiencing myasthenic crisis;
  • SSc: involving lungs and exist severe ILD and severe PAH, or patients with scleroderma renal crisis.
  • Any of the following conditions exist:
Show all 30Show fewer
  • Positive for Hepatitis B surface antigen (HBsAg)/core antibody (HBcAb)/e-antibody (HBeAb)/e antigen (HBeAg);
  • Positive for Hepatitis C virus (HCV) antibody;
  • Positive for human immunodeficiency virus (HIV) antibody;
  • Positive CMV DNA or above the upper limit of detection;
  • Positive for syphilis antigen or antibody.
  • Other uncontrolled active infections exist at screening.
  • Creatinine clearance <50 mL/min.
  • Estimated glomerular filtration rate <45 mL/min/1.73m² (calculated using the MDRD creatinine equation from the Chronic Kidney Disease Epidemiology Collaboration; or serum creatinine >2.0 mg/dL.
  • History of major organ transplantation (such as heart, lung, liver, kidney) or bone marrow/hematopoietic stem cell transplantation.
  • History within 6 months before screening of any of the following cardiovascular diseases: NYHA class III or IV heart failure, myocardial infarction, unstable angina, uncontrolled or symptomatic atrial arrhythmia, any ventricular arrhythmia, or other clinically significant heart disease.
  • History of ≥grade 2 bleeding within 4 weeks before screening, or requiring long-term continuous anticoagulant therapy (such as warfarin, low molecular weight heparin, or factor Xa inhibitors, etc.).
  • History within the past 24 weeks/6 months of severe active central nervous system disease or pathology, including but not limited to: cerebrovascular accident, aneurysm, epilepsy, convulsions/seizures, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychiatric disorders. Stable patients will be assessed by the investigator for eligibility.
  • Diagnosed with malignant tumors within the past 5 years. The following are excluded: non-melanoma skin cancer treated with radical therapy, localized prostate cancer, biopsy-confirmed cervical carcinoma in situ or squamous intraepithelial lesions detected by cervical smear, and completely resected breast carcinoma in situ.
  • History of live vaccine administration within the past 4 weeks.
  • Have received any of the following treatments:
  • Preventive therapy with short-acting oral antiretroviral drugs within 7 days before first administration, or preventive therapy with longacting antiretroviral drugs within 2 years before first administration;
  • Plasma exchange, plasmapheresis, or hemodialysis within 14 days before screening;
  • Any other clinical study drug within 4 weeks before screening. However, if the study treatment was ineffective or the disease progressed, and at least 3 half-lives had passed before screening, enrollment is allowed;
  • History of bone marrow transplantation, gene therapy, adoptive cell therapy, or any type of CAR-T cell therapy;
  • Previously received any mRNA-LNP product or other LNP-based drugs.
  • Unable to complete washout of previous treatment drugs as required within 4 weeks before first administration, or unable to maintain stable doses of concomitant medications for autoimmune diseases.
  • Pregnant or breastfeeding women.
  • Allergic to supportive medications required for managing CAR-T cell therapy toxicities (e.g., tocilizumab).
  • Other situations where the investigator judges that the trial participant has poor compliance or is unwilling or unable to adhere to the study protocol.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Qiubai Li, professor contact

85726808 ext. 027

qiubaili@hust.edu.cn

Di Wu contact

18790696175 ext. 86

373181302@qq.com

China1 site, 1 recruiting

  • Union hospital Tongji medical college Huazhong university of science and technology

    Wuhan, Hubei, 430022

    Qiubai Li, 85726808 ext. 027, qiubaili@hust.edu.cn

    Di Wu, 18790696175 ext. 86, 373181302@qq.com

    Recruiting

Other trials in China

About this study

Official title: Exploratory Clinical Study of EVM18001 Injection in the Treatment of Active Refractory Systemic Lupus Erythematosus, Myasthenia Gravis and Scleroderma

A FIH, single arm, open-label, Investigator Initiated Trial (IIT) study to evaluate the safety and tolerability of EVM18001 in the treatment of active refractory autoimmune diseases (SLE, MG, and SSc), and determine the recommended dose for subsequent treatment. At the same time, the PK/PD characteristics of EVM18001 will be evaluated, preliminary efficacy will be observed, and related biomarkers and immunogenicity will be explored.

Read the detailed description

The main questions it aims to answer are:

  • If EVM18001 is safe and tolerate in patients with active refractory autoimmune diseases (SLE, MG, and SSc)?
  • What the recommended dose for subsequent treatment?
  • What the PK/PD profiles of EVM18001 in patients with active refractory autoimmune diseases (SLE, MG, and SSc)?
  • What the efficacy of EVM18001 in patients with active refractory autoimmune diseases (SLE, MG, and SSc)#
  • What the biomarkers and immunogenicity of EVM18001 in treating of patients with active refractory autoimmune diseases (SLE, MG, and SSc)?

Participants will:

  • Inform the investigator in a timely manner when unable to attend a visit.
  • Report any changes in their health condition to the study doctor, including discomfort or other health issues during the screening period.
  • Inform the study doctor of any other medications taken before and during the study; inform the study doctor before starting any new medications.
  • Be informed of any medications which may be affected by the study drug that should not be used during the study.
  • Agree to use effective contraception during the study and for 12 months after the last infusion of EVM18001EVM injection.
Being tested
EVM18001 Injection
Keywords
Active Refractory Systemic Lupus Erythematosus, Myasthenia Gravis, Scleroderma, EVM18001, CAR-T, Refractory Autoimmune Diseases
Medical subject headings
Lupus Erythematosus, Systemic, Scleroderma, Diffuse, Myasthenia Gravis, Autoimmune Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • EVM18001 InjectionBiological

    All enrolled participants will receive multiple doses of EVM18001 according to the assigned dosage group.

Study groups in NCT07470151
Study groupRoleWhat they receive
EVM18001 InjectionExperimentalAll enrolled participants will receive multiple doses of EVM18001 according to the assigned dosage group.
Receives: Biological: EVM18001 Injection

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Evaluate the safety/tolerability of EVM18001 in patients with SLE/MG/SSc by rates and severity of AE/SAE.

    Subsequent recommended dose will be determined by the results of the clinical study.

    Measured: Day 1 ~ Month 24

  2. Determine the subsequent recommended dose of EVM18001 in patients with SLE/MG/SSc.

    Subsequent recommended dose will be determined by the results of the clinical study.

    Measured: Day 1~ Month 24

  3. Evaluate the efficacy of EVM18001 in patients with SLE/MG/SSc by proportion of patients get relief during the whole study.

    Evaluated by PI

    Measured: Day 1 ~ Month 24

  4. Evaluate the efficacy of EVM18001 in patients with SLE/MG/SSc by Duration of Response (DOR).

    Evaluated by PI

    Measured: Day 1 ~ Month 24

  5. Cmax of EVM18001 and CAR-T cells.

    Samples will be sent to the central laboratory for testing and analysis. The content of peripheral blood mRNA EVM18001 will be detected by quantitative polymerase chain reaction (qPCR), the concentration of ionizable lipid L84 will be measured by liquid chromatography-mass spectrometry (LCMS), and the pharmacokinetic characteristics after EVM18001 administration will be monitored by detecting peripheral blood CAR-T cells using flow cytometry.

    Measured: Day1~ Day29

  6. AUC0-t of EVM18001 and CAR-T cells.

    Samples will be sent to the central laboratory for testing and analysis. The content of peripheral blood mRNA EVM18001 will be detected by quantitative polymerase chain reaction (qPCR), the concentration of ionizable lipid L84 will be measured by liquid chromatography-mass spectrometry (LCMS), and the pharmacokinetic characteristics after EVM18001 administration will be monitored by detecting peripheral blood CAR-T cells using flow cytometry.

    Measured: Day1~ Day29

  7. Detection of CAR expression on the surface of immune cells in peripheral blood.

    PD indicator

    Measured: Day1~ Day29

Secondary outcomes (7)

  1. Evaluate the efficacy of EVM18001 in patients with SLE/MG/SSc by proportion of patients relieve after 6 months.

    Evaluated by PI

    Measured: Day 1 ~ Month 24

  2. Evaluate the efficacy of EVM18001 in patients with SLE/MG/SSc by proportion of patients get relapse during the whole study.

    Evaluated by PI

    Measured: Day 1 ~ Month 24

  3. Evaluate the efficacy of EVM18001 in patients with SLE/MG/SSc by proportion of patients achieving no hormone/immunosuppressant use or low-dose hormone use during the whole study.

    Evaluated by PI

    Measured: Day 1 ~ Month 24

  4. PK detection of EVM18001 in peripheral blood.

    Samples will be sent to the central laboratory for testing and analysis. The content of peripheral blood mRNA EVM18001 will be detected by quantitative polymerase chain reaction (qPCR), the concentration of ionizable lipid L84 will be measured by liquid chromatography-mass spectrometry (LCMS), and the pharmacokinetic characteristics after EVM18001 administration will be monitored by detecting peripheral blood CAR-T cells using flow cytometry.

    Measured: Day1~ Day29

  5. Tmax of EVM18001 and CAR-T cells.

    Samples will be sent to the central laboratory for testing and analysis. The content of peripheral blood mRNA EVM18001 will be detected by quantitative polymerase chain reaction (qPCR), the concentration of ionizable lipid L84 will be measured by liquid chromatography-mass spectrometry (LCMS), and the pharmacokinetic characteristics after EVM18001 administration will be monitored by detecting peripheral blood CAR-T cells using flow cytometry.

    Measured: Day1~ Day29

  6. AUC0-30d of EVM18001 and CAR-T cells.

    Samples will be sent to the central laboratory for testing and analysis. The content of peripheral blood mRNA EVM18001 will be detected by quantitative polymerase chain reaction (qPCR), the concentration of ionizable lipid L84 will be measured by liquid chromatography-mass spectrometry (LCMS), and the pharmacokinetic characteristics after EVM18001 administration will be monitored by detecting peripheral blood CAR-T cells using flow cytometry.

    Measured: Day1~ Day29

  7. Number of decreased B cells in peripheral blood.

    PD indicator

    Measured: Day1~ Day29

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Mar 2026
  2. Study start12 Mar 2026 (estimated)
  3. Primary completionNov 2026 (estimated)
  4. Study completionDec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential
Model description
DL1 and DL2 use an accelerated titration design, enrolling 1-3 trial participants. If the first participant in each dose group does not experience dose-limiting toxicity (DLT), the dose is rapidly escalated to the next group; if DLT occurs, the Safety Review Committee (SRC) will discuss whether to reduce the dose (DL1 will be reduced to DL-1) or to expand enrollment by 3 participants. DL3 uses a "3#+#3" dose escalation, enrolling 3 participants; if no DLT occurs, the dose is rapidly escalated to the next group; if DLT occurs, enrollment is expanded by 3 participants. DL4 also uses a "3#+#3" dose escalation, first enrolling 3 participants; if none of the first 3 experience DLT, further dose escalation may be considered; if 1 of the first 3 participants experiences DLT, 3 additional participants are enrolled; if ≥2 of the first 3 participants, or ≥2 of a total of 6 participants, experience DLT, dose escalation is stopped.
Masking
None (open label)
Enrolment
12 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07470151
Sponsor's protocol ID
EVM18CX01
Status last verified
Mar 2026
First submitted
10 Mar 2026
Last updated
13 Mar 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing EVM18001 Injection in people with System Lupus Erythematosus(SLE) and Scleroderma, run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 29 inclusion and 30 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 13 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Qiubai Li, professor (85726808 ext. 027, qiubaili@hust.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Evaluate the safety/tolerability of EVM18001 in patients with SLE/MG/SSc by rates and severity of AE/SAE. (time frame: Day 1 ~ Month 24). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07470151.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Mar 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in